Phibro Animal Health saw its IBD SmartSelect Composite Rating rise to 96 Tuesday, up from 92 the day before.
The upgrade means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. History shows the top market performers tend to have a 95 or higher score as they launch their major moves.
Phibro Animal Health is not currently near a proper buy zone. See if the stock goes on to form a new chart pattern and offer a new buying opportunity. Note that it is a thinly traded stock, with average daily dollar volume under $8 million.
Discover The 3 Keys To Successful Stock Investing
The stock has a 92 EPS Rating, which means its recent quarterly and longer-term annual earnings growth tops 92% of all stocks.
Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.
The company reported 64% EPS growth for Q2. Revenue growth climbed 24%, up from 13% in the prior report. The company has now posted increasing growth in each of the last two reports.
Phibro Animal Health holds the No. 1 rank among its peers in the Medical-Ethical Drugs industry group. Jazz Pharmaceuticals and Novartis ADR are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
